Forbes preclinical data

In an 18-week study with transgenic apoE-deficient mice, the group treated with FCP-3P1 demonstrated a 40 percent reduction of circulating cholesterol levels within four weeks, which persisted until the study's end. In addition, the area of atherosclerotic lesions was reduced by about 50 percent.

ApoE-deficient mice lack a plasma protein component necessary for the uptake of cholesterol from the bloodstream. ...